

M E D I C A L
CROSSFIRE®

Multidisciplinary Discussions on the Application of Novel EGFR Exon 20 Targeted Regimens for NSCLC Management

IN-PERSON + VIRTUAL
SATELLITE SYMPOSIUM

SUNDAY, JUNE 5, 2022

7:00 PM - 9:00 PM CDT

PROGRAM CHAIR

Pasi A. Jänne, MD, PhD

For more information, visit us at...

gotoper.com



STAY CONNECTED! Follow us @GoToPER and share your thoughts by using #gotoPER.



WELCOME

Dear Colleague,

On behalf of Physicians' Education Resource®, LLC (PER®), we would like to welcome you and thank you for choosing to attend **Medical Crossfire®: Multidisciplinary Discussions on the Application of Novel *EGFR* Exon 20 Targeted Regimens for NSCLC Management**.

This live educational symposium brings together a panel of experts from a range of disciplines to discuss emerging treatment options for patients with non-small cell lung cancer (NSCLC) harboring *EGFR* exon 20 insertion mutations. The dynamic format Medical Crossfire® format encourages discussion about interactions and decisions faced by your and your colleagues within your multidisciplinary teams.

In working together with PER®, we strive to make this activity, along with all of PER®'s accredited continuing education (CE) activities, both useful and impactful for health care professionals like you who are involved with the care of patients with NSCLC.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of cancer. Let's work together to make this an educational experience that will make a positive difference for our patients!

We hope that you enjoy your experience at this first-class PER® symposium and that you can attend another PER® accredited CE activity soon.

Regards,

Pasi A. Jänne, MD, PhD

Director, Lowe Center for Thoracic Oncology
Professor of Medicine, Harvard Medical School
Director, Belfer Center for Applied Cancer Science
Dana Farber Cancer Institute
Boston, MA

Phil Talamo, CHCP

President
Physicians' Education Resource®, LLC
Cranbury, NJ
ptalamo@gotoper.com



AGENDA

6:30 PM	Registration & Dinner	
7:00 PM	Introduction and presession survey	Pasi A. Jänne, MD, PhD
7:10 PM	Unraveling the Complexity of <i>EGFR</i> Mutations: What Oncologists Need to Know About <i>EGFR</i> Exon 20 Insertions	Pasi A. Jänne, MD, PhD
7:30 PM	Decoding Molecular Testing Results: A Case-Based Discussion	Jason Chang, MD
7:45 PM	Accumulating Clinical Evidence for <i>EGFR</i> Exon 20-Targeted Approaches: Applications for the Clinic Today and Beyond	Gregory Riely, MD, PhD
8:10 PM	Practical Issues and Optimizing Delivery of Care With <i>EGFR</i> Exon 20-Targeted Agents	Beth Sandy, MSN, CRNP
8:30 PM	What's On the Radar: Data Reporting at the Annual Meeting and Clinical Trials Underway	Faculty Panel
8:40 PM	Medical Crossfire® From the Floor: Question & Answer Session	Faculty Panel
8:50 PM	Postsession Survey and Conclusion	
9:00 PM	Adjourn	

Upcoming PER® Conferences

2022

	6th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards		June 25
	21st Annual International Congress on the Future of Breast Cancer® East	New York City, NY	July 15-16
	6th Annual Live Medical Crossfire®: Hematologic Malignancies	New York City, NY	July 16
	23rd Annual International Lung Cancer Congress®	Huntington Beach, CA	July 28-30
	21st Annual International Congress on the Future of Breast Cancer® West	San Diego, CA	July 29-30
	6th Annual School of Nursing Oncology	San Diego, CA	July 29-30
	20th Annual School of Breast Oncology®	Atlanta, GA	November 3-5
	40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®	New York City, NY	November 9-11
	17th Annual New York Lung Cancers Symposium	New York City, NY	November 12
	7th Annual International Congress on Immunotherapies in Cancer™	New York City, NY	December 10

 Virtual Conference  In-Person + Virtual Conference

ACTIVITY OVERVIEW

Target Audience

This educational activity is directed toward medical oncologists, surgical oncologists, pathologists, nurse practitioners, physician assistants, nurses, and other oncology health care professionals.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Assess optimal molecular testing strategies for patients with NSCLC and *EGFR* exon 20 insertions along the continuum of care
- Describe the role of multidisciplinary team members in the delivery of care for patients with NSCLC and *EGFR* exon 20 insertions
- Apply safety and efficacy results from clinical trials assessing targeted approaches for the management of patients with advanced NSCLC and *EGFR* exon 20 insertions
- Summarize approaches to mitigate and manage treatment-related adverse events associated with the use of targeted therapy in patients with NSCLC and *EGFR* exon 20 insertions

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER® website by 12 PM EDT on Monday, June 6, 2022. To access these materials, please visit <https://www.gotoper.com/egfr0622iss-esyl>.

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit <https://www.gotoper.com/egfr0622iss-eval>.

The online evaluation and request for credit will be available immediately following the program and will remain available until September 5, 2022.

Accreditation/Designation of Credit

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC, and Takeda Pharmaceuticals U.S.A, Inc.

Thank you for attending **Medical Crossfire®: Multidisciplinary Discussions on the Application of Novel EGFR Exon 20 Targeted Regimens for NSCLC Management**

To register for upcoming accredited CE live activities
or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future
PER® accredited CE activities.

ACTIVITY OVERVIEW

Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: Jason Chang, MD and the staff of Physicians' Education Resource®, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose*:

Faculty	Grant/Research Support	Consultant	Speakers' Bureau	Shareholder
Pasi A. Jänne, MD, PhD	Astellas Pharmaceuticals, AstraZeneca, Daiichi Sankyo, PUMA, Eli Lilly pharmaceuticals, Boehringer Ingelheim, Revolution Medicines, Takeda Oncology	AstraZeneca, Boehringer Ingelheim, Pfizer, Roche/Genentech, Chugai Pharmaceuticals, Acea Biosciences, Ignyta, LOXO Oncology, Eli Lilly pharmaceuticals, Araxes pharmaceuticals, SFJ Pharmaceuticals, Voronoi, Daiichi Sankyo, Biocartis, Novartis, Sanofi, Takeda Oncology, Mirati Therapeutics, Transcenta, Silicon Therapeutics, Syndax, Nuvalent, Bayer, Eisai, Allorion Therapeutics, Accutar Biotech, Abbvie		Gatekeeper Pharmaceuticals
Gregory Riely, MD, PhD	Mirati, Pfizer, Takeda, Novartis, Roche, Merck	Mirati (uncompensated), Pfizer (uncompensated), Verastem (uncompensated)		
Beth Sandy, MSN, CRNP		Janssen	Merck, AstraZeneca, Takeda, Amgen, Jazz	

**Information accurate at time of posting*

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Physician Payments Sunshine Act

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.

Program Chair



Pasi A. Jänne, MD, PhD

Professor of Medicine
Harvard Medical School
Director, Lowe Center for Thoracic Oncology
Director, Belfer Center for Applied Cancer Science
Dana Farber Cancer Institute
Boston, MA

Pasi A. Jänne, MD, PhD, received his medical degree and doctorate from the University of Pennsylvania. He completed postgraduate training in internal medicine at Brigham and Women's Hospital and in medical oncology at Dana-Farber Cancer Institute. He is a professor of medicine at Harvard Medical School and the director of the Lowe Center for Thoracic Oncology and the Che-Huang Center for EGFR Mutant Lung Cancers. Dr Jänne also serves as the scientific director of the Belfer Center for Applied Cancer Science. His main research interests include the therapeutic relevance of oncogenic alterations in lung cancer. Dr Jänne was one of the co-discoverers of *EGFR* mutations; he has led the development of therapeutic strategies for patients with *EGFR*-mutant lung cancer.

Faculty



Jason Chang, MD

Pathologist
Molecular Genetic Pathology and Thoracic Pathology
Memorial Sloan Kettering Cancer Center
New York, NY

Jason Chang, MD, has clinical expertise in thoracic pathology and molecular pathology. As part of the Thoracic Disease Management Team, Dr Chang works closely with colleagues in surgery, medical oncology, and radiation therapy to care for people with lung, pleural, and mediastinal tumors. He provides accurate diagnosis, grading, and staging for people with these tumors. As a molecular genetic pathologist, Dr Chang primarily is involved in the diagnosis of genetic abnormalities in cancer. His current research interests include thymoma/thymic carcinoma and molecular abnormalities in lung cancer.



Gregory Riely, MD, PhD

Vice Chair, Clinical Research
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Gregory Riely, MD, PhD, is a medical oncologist in the department of Medicine at Memorial Sloan Kettering Cancer Center. He specializes in treating patients with lung cancer and thymic tumors (thymoma, thymic carcinoma). Dr Riely received his medical degree and doctorate from Case Western Reserve University. He completed fellowship training in medical oncology at Memorial Sloan Kettering Cancer Center. He is involved in the design and direction of research involving patients with non-small cell lung cancer that harbors *EGFR*, *KRAS*, *BRAF*, or *EML4-ALK* mutations. He has authored and co-authored numerous peer-reviewed articles.

FACULTY




Beth Sandy, MSN, CRNP

Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
Hospital of the University of Pennsylvania
Philadelphia, PA

Beth Sandy, MSN, CRNP, is a nurse practitioner working in thoracic medical oncology at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia. She specializes in the treatment of patients with lung cancer. She has published and lectured nationally and internationally on lung cancer and supportive care associated with lung cancer patients. Ms Sandy is a board member of the International Thoracic Oncology Nurses Forum and an associate editor for the Journal of the Advanced Practitioner in Oncology.

Experience
the new
gotoper.com



Streamlining
education
for the busy
clinician



ASCO Direct™

HIGHLIGHTS

2022 Official Annual Meeting Review

Learn from leading experts about important, potentially practice-changing data in oncology and hematology.

Dallas, TX
June 18

Charlotte, NC
July 9

Nashville, TN
July 9

New York, NY
July 23

VIRTUAL
OPTIONS
AVAILABLE

40% off registration! Use code **ADH22**



Scan with smartphone
to explore the series

PER®
Physicians'
Education
Resource, LLC
gotoper.com

**CELEBRATE THE 40TH ANNIVERSARY
OF CFS® LIVE IN NYC**

**40th Annual
CFS**®

Chemotherapy Foundation
SYMPOSIUM

Innovative Cancer Therapy for Tomorrow®

SAVE
THE
DATE!

NOVEMBER 9 – 11, 2022

New York Marriott Marquis • New York, NY

In-person + Virtual Conference

This activity
is approved
for AMA PRA
Category 1
Credit™.

 **100** EXPERT
FACULTY
MEMBERS

 **25** TUMOR
TYPES

 **3** DAYS

 **1** MEETING

35% off registration! Use code **CFS22BF**



Scan with smartphone or visit the link below
gotoper.com/cfs22

PER®
Physicians'
Education
Resource, LLC
gotoper.com